Skip to main content

Table 1 Results of the outlet census and anti-malarial audit by country and survey year

From: Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries

Country

Year

Screened (N outlets)

Anti-malarial audit completed (N outlets)

Anti-malarials audited (N drugs)

QAACT audited (N drugs)

Non-QAACT audited (N drugs)

West and Central Africa

 Benin

2009

1670

844

5233

859

1629

2011

2891

1237

8987

1396

3925

2014

4332

1806

14,378

2483

6454

 DRC, Kinshasa

2009

2368

766

8437

151

1911

2013

3364

931

12,291

216

6022

2015

1168

1056

16,287

853

7389

 DRC, Katanga

2013

2270

771

6493

854

1975

2015

1052

993

8050

1507

2025

 Nigeria

2009

5456

2113

20,841

1192

4624

2011

7938

1486

13,391

2119

1610

2013

5148

1714

14,358

4799

2058

2015

13,483

3473

33,539

9586

7173

East Africa

 Kenya

2010

13,897

1888

8376

2052

2276

2011

11,383

1854

9544

3669

2153

2014

12,676

2133

9899

3234

3133

 Tanzania

2010

3120

624

5544

416

1415

2011

3702

787

9701

2045

2300

2014

4724

2129

17,307

4905

2314

 Uganda

2010

11,153

2410

14,427

2893

3785

2011

16,207

3138

20,283

5495

4683

2013

7932

3307

19,777

7182

4314

2015

9438

4328

26,640

7380

7238

Southern Africa

 Madagascar

2010

6769

2414

5579

1790

184

2011

10,046

2360

7234

3233

172

2013

10,149

1756

6101

3851

116

2015

 13,481

 1040

 3170

1501

4

 Zambia

2009

3378

435

1783

601

158

2011

5436

781

3355

1036

594

2014

5878

980

5012

1260

1496